LONDON, May 7, 2014 /PRNewswire/ --
The US markets saw a negative sentiment on Tuesday, May 6, 2014, with the NASDAQ Composite closing at 4,080.76, down 1.38%, the Dow Jones Industrial Average ending the session 0.78% lower at 16,401.02, and the S&P 500 edging 0.90% lower to finish the trading session at 1,867.72. The loss were broad based with nine out of the ten sectors finishing lower. The S&P 500 Health Care Sector Index ended the day at 666.48, down 0.91%, whereas the index has gained 4.08% in the previous three months. Investor-Edge has initiated coverage on the following equities: Dendreon Corporation (NASDAQ: DNDN), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Idera Pharmaceuticals Inc. (NASDAQ: IDRA) and Vertex Pharmaceuticals Inc. (NASDAQ: VRTX). Free technical research on DNDN, KERX, IDRA and VRTX can be downloaded upon signing up at:
Dendreon Corp.'s stock finished the Tuesday's session 3.60% lower at $2.41. A total of 1.93 million shares were traded, which was below its three months average volume of 3.01 million shares. The stock vacillated between $2.41 and $2.52 during the session. Over the last one month and the previous three months, Dendreon Corp.'s shares have lost 15.14% and 9.40%, respectively. Additionally, from the beginning of 2014, the company's stock has declined 19.40%. The company's shares are trading below their 50-day and 200-day moving averages. Moreover, the stock's 50-day moving average of $2.86 is less than its 200-day moving average of $3.02. Dendreon Corp.'s stock has a Relative Strength Index (RSI) of 32.95. Sign up today to read free research on DNDN at:
On Tuesday, shares in Keryx Biopharmaceuticals Inc. fluctuated between $14.14 and $14.75 before ending the session 1.10% lower at $14.33. The stock reported a trading volume of 1.46 million shares, below its three months average volume of 2.69 million shares. Keryx Biopharmaceuticals Inc.'s shares have lost 2.32% in the previous three trading sessions and 9.99% in the last one month, while the stock has gained 10.66% on YTD basis. The stock is trading above its 200-day moving average of $12.51, while the 200-day moving average is below Keryx Biopharmaceuticals Inc.'s 200-day moving average of $15.25. Moreover, shares of the company have an RSI of 47.60. Sign up today to read free research on KERX at:
Shares in Idera Pharmaceuticals Inc. declined 4.59%, to close the day at $2.70. The stock recorded a trading volume of 1.27 million shares, much below its three months average volume of 3.62 million shares. The stock oscillated between $2.66 and $2.90 during the session. Over the last three trading sessions and over the past one month, Idera Pharmaceuticals Inc.'s shares have lost 9.40% and 27.22%, respectively. Further, the stock has declined 41.68% since the start of this year. The stock is trading below its 50-day and 200-day moving averages of $4.50 and $3.14, respectively. Additionally, Idera Pharmaceuticals Inc.'s stock has an RSI of 37.05. Sign up today to read free research on IDRA at:
On Tuesday, shares in Vertex Pharmaceuticals Inc. recorded a trading volume of 1.33 million shares, lower than its three months average volume of 1.57 million shares. The stock ended the day at $66.56, which was 2.70% below its previous day's closing of $68.41, and registered an intraday range of $66.47 and $68.75. Although Vertex Pharmaceuticals Inc.'s shares have advanced 1.09% in the last one month, it has lost 3.47% in the previous three trading sessions and 10.42% on YTD basis. The company's stock is trading below its 50-day and 200-day moving averages of $72.55 and $74.49, respectively. Furthermore, shares of Vertex Pharmaceuticals Inc. have an RSI of 50.51. Sign up today to read free research on VRTX at:
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.